Respiratory Syncytial Virus (RSV) Diagnostic - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The respiratory syncytial virus diagnostics market size is expected to grow from USD 1.24 billion in 2025 to USD 1.35 billion in 2026 and is forecast to reach USD 2.04 billion by 2031 at 8.62% CAGR over 2026-2031. This report Segments the Industry Into by Product (Kits and Assays, Instruments, Other Products), by Method (Molecular Diagnostics, Rapid Antigen Detection Tests, Immunoassays, Flow Cytometry, Chromatography, Other Methods), by End-User (Hospitals and Clinics, Clinical Laboratories, Other End-Users), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America).

Global Respiratory Syncytial Virus (RSV) Diagnostic Market Trends and Insights

Surging Adoption of Point-of-Care RSV Molecular Panels

• Field studies show that cartridge-based molecular systems deliver results in 0.2 - 3.8 hours versus up to 36 hours for batch PCR, trimming unnecessary antibiotic use and isolation bed days. Community clinics now embed these single-use panels into triage protocols, while large urgent-care chains adopt multiplex cartridges that identify RSV, influenza, and COVID-19 from one swab. Accelerated clinical decisions are raising physician confidence and fuelling repeat procurement, pushing the Respiratory Syncytial Virus diagnostics market deeper into primary-care channels.

Rising Burden of Syncytial Virus Infections

RSV accounts for up to 80 000 US child hospitalisations annually and triggers 100 000-150 000 admissions among adults aged 60+. Globally, WHO attributes roughly 3.6 million paediatric hospitalisations and 100 000 deaths per year to RSV who.int. The sheer caseload is reinforcing payer support for early detection, sustaining long-run growth in the Respiratory Syncytial Virus diagnostics market.

High False-Negative Rates of First-Generation Lateral-Flow Antigen Tests

Meta-analysis of paediatric studies shows that legacy antigen strips exhibit markedly lower sensitivity than RT-PCR, raising risk of missed cases and misguided cohorting. Hospitals in resource-constrained regions that still rely on these strips may delay treatment or isolation, dampening clinician trust and temporarily tempering demand in segments of the Respiratory Syncytial Virus diagnostics market.

Other drivers and restraints analyzed in the detailed report include:

• FDA Fast-Track Maternal RSV Vaccines Catalysing Prenatal Screening Uptake
• Increasing Approvals for Syncytial Virus Diagnostic Products
• Stringent Regulations and Low Detection Limits of Immunoassays

Segment Analysis

Kits & assays generated the largest revenue in 2025 as clinicians continue to favour single-use cartridges and ELISA plates validated across age groups. Their 36.02% share translates into USD 0.45 billion of Respiratory Syncytial Virus diagnostics market size, supported by recurrent reagent sales. Software and analytics, although contributing a smaller absolute sum, is expected to post the quickest gains. Cloud dashboards that convert cycle-threshold curves into predictive severity scores are showing 0.811 AUC-ROC in early trials, bolstering purchasing interest among tele-health operators. Instruments remain essential for laboratories processing pooled respiratory panels, while reagents and consumables drive annuity-style cash flows for OEMs.

Growing emphasis on data-rich reporting grants software packages a central role in stewardship programmes tracking antimicrobial usage. Integrated AI modules are forecast to raise laboratory productivity by automating result validation, a trend that will reinforce double-digit growth for this niche. Consequently, the Respiratory Syncytial Virus diagnostics market is shifting from pure consumables toward hybrid hardware-software ecosystems that amplify clinical insight.

Rapid antigen detection accounted for 27.05% of Respiratory Syncytial Virus diagnostics market share in 2025, owing to affordability and CLIA-waived status. These strips are widely stocked in paediatric units and nursing homes, underpinning broad geographic reach. Molecular diagnostics, however, is on a sharper 10.22% growth curve, leveraging CRISPR-based readouts and extraction-free protocols that cut sample prep time by 60%. The Respiratory Syncytial Virus diagnostics market size attributable to molecular formats is projected to surpass USD 0.86 billion by 2031 as price per panel narrows relative to antigen tests.

Advances in digital microfluidics and nanopore sequencing are pushing limits of detection below 10 copies/ml, capturing low-viral-load cases in immunocompromised adults. Chromatographic immunoassays hold a steady position in reference labs that prefer batch throughput, while emerging nanobubble platforms offer early-stage promise for decentralised testing. Collectively, these innovations are recalibrating the method mix and elevating overall assay accuracy in the Respiratory Syncytial Virus diagnostics market.

Complete Report Scope:

• By Product
  • Kits & Assays
  • Instruments
  • Reagents & Consumables
  • Software & Analytics
• By Method
  • Molecular Diagnostics (RT-PCR, CRISPR, Isothermal NAAT)
  • Rapid Antigen Detection (Immunochromatographic/Lateral Flow)
  • Chromatographic Immunoassays (Enzyme-based)
  • Others
• By Sample Type
  • Nasal Swabs
  • Nasopharyngeal Aspirates
  • Saliva
  • Whole Blood/Serum
• By End User
  • Hospitals & Clinics
  • Diagnostic Reference Laboratories
  • Home-Care
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America generated 39.22% of revenues in 2025, driven by widespread insurance coverage and robust RSV surveillance networks that feed hospital dashboards in near real time. Early uptake of maternal vaccination and monoclonal prophylaxis is further expanding routine newborn screening. Amid these dynamics, the Respiratory Syncytial Virus diagnostics market benefits from established distributors and laboratory automation that accelerates test throughput during winter virus peaks.

Europe maintains a strong second position. National winter-respiratory frameworks mandate RSV testing alongside influenza, lifting baseline volumes across public hospitals. Germany, France, and the United Kingdom continue to procure multiplex PCR systems for integrated respiratory surveillance. Eastern European countries are adopting pooled-sample algorithms to mitigate reagent costs, gradually enlarging regional scope for the Respiratory Syncytial Virus diagnostics market.

Asia-Pacific posts the fastest expansion at 11.21% CAGR. China, Japan, and Australia are scaling neonatal intensive-care beds and embedding RSV panels into provincial reimbursement lists. India’s private laboratories are equipping tier-2 city hubs with cartridge PCR, narrowing rural access gaps. Government pandemic funds redirected toward respiratory preparedness are catalysing public-private partnerships in Indonesia, Malaysia, and the Philippines. Collectively, these investments underpin durable growth for the Respiratory Syncytial Virus diagnostics market across the region. Middle East & Africa and South America, though smaller in absolute size, are witnessing rising public-sector tenders for rapid antigen kits as part of broader acute-respiratory disease initiatives, paving long-term expansion pathways.

List of Companies Covered in this Report:

• Abbott Laboratories
• Roche
• Thermo Fisher Scientific
• Beckton Dickinson
• QuidelOrtho
• bioMérieux
• Siemens Healthineers
• Danaher
• Hologic
• DiaSorin SpA (Luminex)
• QIAGEN
• PerkinElmer
• Meridian Bioscience
• Bio-Rad Laboratories
• Sekisui Diagnostics
• Altona Diagnostics GmbH
• SD Biosensor Inc.
• Seegene
• QuantuMDx Group Limited
• Sherlock Biosciences

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support